Unilabs is implementing Stratipath Breast for enhanced breast cancer diagnostics at Capio S:t Göranâs Hospital
Capio St Göranâs Hospital is one of the largest breast cancer clinics in Sweden treating more than 600 breast cancer patients annually. With this new collaboration, Unilabs will use Stratipath Breast on a selected group of these patients.
Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics
Stratipath is thrilled to announce a collaboration with Roche, the worldâs largest biotechnology company and the global leader in in-vitro diagnostics.
Stratipath Breast AI-based risk profiling for breast cancer is now available for clinical use in the UK.
Stratipath Breast, is now officially registered with the Medicines and Healthcare products Regulatory Agency (MHRA). This registration allows healthcare providers across the United Kingdom access to the AI-based prognostic tool for breast cancer risk profiling.
Stratipath is proud to be a part of Proscia’s new partner alliance âProscia Readyâ
Stratipath is proud to be a part of Proscia’s new partner alliance âProscia Readyâ.
Stratipath is now a part of Paige AppLab
Stratipath is now a part of Paige AppLab
Stratipath And Proscia Announce Partnership, Paving The Way To Bring Relapse Risk Prediction To More Breast Cancer Patients
Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, and ProsciaÂź, a leading provider of digital and computational pathology solutions, have partnered to help oncologists and pathologists determine the most suitable treatment path for more breast cancer patients.
Professor Jonas Bergh, will be leading our scientific advisory board
Stratipath is happy to announce that one of the most prominent breast oncologists, Professor Jonas Bergh, will be leading the companyâs scientific advisory board. As Stratipath is entering the clinical phase with its first-in-class, CE-IVD solution for AI-driven risk profiling, Stratipath breast and at the same time ramping up the research and development efforts for future solutions, the scientific advisory board will play a crucial role in the companyâs development.
The Swedish deep-tech company Stratipath announces its integration with Sectra, one of the most expanding PACS systems for digital pathology
Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, today announced that it has released its integration with international medical imaging IT company Sectra and their digital pathology solution. This means that Sectra users can use Stratipathâs solution Stratipath Breast within an already existing digital pathology workflow. The application is featured in Sectra Amplifier Marketplace and purchased directly from Stratipath.
First CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients
Stratipath, a global leader in AI-based precision diagnostic solutions, today announced that its AI software for prognostic risk stratification of breast cancers, Stratipath Breast, is now CE-IVD marked. This paves the way for clinical implementation in the European Union. Based on the analysis of digital histopathology whole slide images, stained with haematoxylin and eosin (H&E) the software provides novel decision support to clinicians and enables precision medicine for more patients.
Government grant to provide more accurate breast cancer diagnosis
Vinnova grants SEK 20 million to the Swedish AI Precision Pathology (SwAIPP) consortia to develop and implement AI-based precision diagnostics in cancer care. The consortia consist of Stratipath, Karolinska Institutet, the pathology clinics in the Kalmar, VÀstmanland and SkÄne regions, Microsoft, Roche Diagnostics, Philips, Bröstcancerförbundet, Prevas and Helseplan.
